Adrenomedullin and Adrenomedullin-Targeted Therapy As Treatment Strategies Relevant for Sepsis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Sepsis remains a major medical challenge, for which, apart from improvements in supportive care, treatment has not relevantly changed over the last few decades. Vasodilation and vascular leakage play a pivotal role in the development of septic shock, with vascular leakage being caused by disrupted endothelial integrity. Adrenomedullin, a free circulating peptide involved in regulation of endothelial barrier function and vascular tone, is implicated in the pathophysiology of sepsis. Adrenomedullin levels are increased during sepsis, and correlate with extent of vasodilation, as well as with disease severity and mortality. In vitro and preclinical in vivo data show that administration of adrenomedullin exerts anti-inflammatory, antimicrobial, and protective effects on endothelial barrier function during sepsis, but other work suggests that it may also decrease blood pressure, which could be detrimental for patients with septic shock. Work has been carried out to negate adrenomedullins putative negative effects, while preserving or even potentiating its beneficial actions. Preclinical studies have demonstrated that the use of antibodies that bind to the n-terminus of adrenomedullin results in an overall increase of circulating adrenomedullin levels and improves sepsis outcome. Similar beneficial effects were obtained using co-administration of adrenomedullin and adrenomedullin binding protein-1. It is hypothesized that the mechanism behind the beneficial effects of adrenomedullin binding involves prolongation of its half-life and a shift of adrenomedullin from the interstitium to the circulation. This in turn results in increased adrenomedullin activity in the blood compartment, where it exerts beneficial endothelial-barrier stabilizing effects, whereas its detrimental vasodilatory effects in the interstitium are reduced. Up till now, in vivo data on adrenomedullin-targeted treatments in humans are lacking, however, the first study in septic patients with a n-terminus antibody (Adrecizumab) is currently being conducted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Antimicrobial peptides of multicellular organisms
Zasloff, M. (2002) · Nature · doi:10.1038/415389a · Cited by 8,457 · cited 1×
“This forms an amphipathic structure, which permits bacterial membrane intercalation (106).”
BackgroundFleischmann, C., Scherag, A., Adhikari, N. K. J., Hartog, C. S., Tsaganos, T., Schlattmann, P., Angus, D. C., & Reinhart, K. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0781oc · Cited by 3,548 · cited 10×
“J Clin Endocrinol Metab (1997) 82(1):95–100.”
BackgroundInfluentialEffect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431 · cited 2×
“8310 clearance, and limits toxicity (154).”
BackgroundAdrenomedullin: A Novel Hypotensive Peptide Isolated from Human Pheochromocytoma
Kitamura, K., Kangawa, K., Kawamoto, M., Ichiki, Y., Nakamura, S., Matsuo, H., & Eto, T. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1451 · Cited by 2,192
RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., & Foord, S. M. (1998) · Nature · doi:10.1038/30666 · Cited by 2,134 · cited 10×
“The endothelial adrenomedullin-RAMP2 system regulates vascular integrity and suppresses tumour metastasis.”
BackgroundInfluentialPoyner, D. R., Sexton, P. M., Marshall, I., Smith, D. M., Quirion, R., Born, W., Muff, R., Fischer, J. A., & Foord, S. M. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.233 · Cited by 804 · cited 3×
“Adrenomedullin(1-52) measured in human plasma by radioimmunoassay:”
BackgroundCaron, K. M., & Smithies, O. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.615 · Cited by 346 · cited 1×
“In knockout models where crucial parts of the ADM–ADM receptor signaling pathway were deleted, development of lethal hydrops fetalis was noted, indicating inadequate development of the endothelial barrier (82, 83).”
Background
Cited by
Xiong, X., Kuang, H., Ansari, S., Liu, T., Gong, J., Wang, S., Zhao, X.-Y., Ji, Y., Li, C., Guo, L., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.028 · Cited by 784
Li, M.-Y., Zhu, X.-L., Zhao, B.-X., Shi, L., Wang, W., Hu, W., Qin, S.-L., Chen, B.-H., Zhou, P.-H., Qiu, B., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1728-5 · Cited by 265
Hijacking Factor H for Complement Immune Evasion
Moore, S. R., Menon, S. S., Cortes, C., & Ferreira, V. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.602277 · Cited by 83
Multi-Omics Endotypes in ICU Sepsis-Induced Immunosuppression
Garduno, A., Cusack, R., Leone, M., Einav, S., & Martin-Loeches, I. (2023) · Microorganisms · doi:10.3390/microorganisms11051119 · Cited by 39
“Other novel therapies that have shown some promising potential benefits are immunoglobulins, non-neutralizing ADM-binding Ab adrecizumab [101,102] has also been shown to inhibit the production of pro-inflammatory cytokines, monoclonal antibodies targeting checkpoint molecules, such as programmed-death 1 protein (PD-1)…”
Background
Metadata
- Authors
- Geven, C., Kox, M., & Pickkers, P.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-02-19
- Volume
- 9
- Pages
- 292-292
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2791367003
- Cited by
- 135
- References
- 8
- FWCI
- 9.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adrenomedullin and Adrenomedullin-Targeted Therapy As Treatment Strategies Relevant for Sepsis. https://app.cochat.ai/papers/10.3389/fimmu.2018.00292
- The paper
- Geven, C., Kox, M., & Pickkers, P. (2018). Adrenomedullin and Adrenomedullin-Targeted Therapy As Treatment Strategies Relevant for Sepsis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2018.00292
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.